Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT016
MIFTS: 67

Hepatitis B

Categories: Infectious diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis B

About this section

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 38 12 76 55 43 44 15 73
Hepatitis B, Chronic 44 73
Hepatitis B Infection 12
Chronic Hepatitis B 12
Hepatitis B Chronic 55
Serum Hepatitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases
Anatomical: Liver diseases Gastrointestinal diseases Immune diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2043
NCIt 50 C3097
Sources

Summaries for Hepatitis B

About this section
MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b, chronic, is related to hepatitis d and hepatitis c, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis B is LAMTOR5 (Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5), and among its related pathways/superpathways are Immune response Role of DAP12 receptors in NK cells and Kaposi's sarcoma-associated herpesvirus infection. The drugs Emtricitabine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and t cells.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, transmitted by blood transfusions, and transmitted by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Sources

Related Diseases for Hepatitis B

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 33.9 F2 GPT IFNA2
2 hepatitis c 31.9 GPT IFNA1 IFNA2 IFNAR2 TNF
3 liver disease 31.8 AFP ALB F2 GPT IFNA1 TNF
4 hepatitis 31.5 AFP F2 GPT IFNA1 IFNA2 IFNAR2
5 cryoglobulinemia, familial mixed 31.3 IFNA1 IFNA2
6 rubella 31.1 IFNAR2 IL10RB TNF
7 mumps 31.1 IFNAR2 IL10RB TNF
8 acute liver failure 31.0 ALB F2 GPT
9 schistosomiasis 30.8 ALB F2 TNF
10 liver cirrhosis 30.7 AFP ALB F2 GPT IFNA1
11 non-a-e hepatitis 30.6 ALB F2
12 nonalcoholic steatohepatitis 30.6 F2 GPT TNF
13 hepatitis e 30.5 ALB F2 GPT TNF
14 portal hypertension 30.5 ALB F2 GPT TNF
15 acquired immunodeficiency syndrome 30.5 ALB IFNA1 TNF
16 alcoholic hepatitis 30.4 ALB F2 GPT TNF
17 viral hepatitis 30.4 AFP ALB F2 GPT IFNA1 IFNA2
18 peritonitis 30.4 ALB F2 TNF
19 biliary atresia 30.3 ALB GPT SLC10A1
20 typhoid fever 30.2 ALB F2 TNF
21 meningitis 30.2 ALB MBL2 TNF
22 hepatic encephalopathy 30.1 ALB F2 GPT TNF
23 cholangitis 30.1 ALB F2 GPT TNF
24 hepatitis a 30.0 AFP ALB F2 GPT IFNA2 TNF
25 cholecystitis 30.0 ALB F2 GPT
26 endocarditis 30.0 ALB F2 TNF
27 hemorrhagic fever 29.9 ALB F2 GPT TNF
28 esophageal varix 29.9 AFP ALB F2
29 eclampsia 29.9 ALB F2 TNF
30 alcoholic liver cirrhosis 29.8 AFP ALB F2
31 cholestasis 28.9 F2 GPT SLC10A1
32 ulcerative colitis 28.8 IL10RB MIR21 TNF
33 cholangiocarcinoma 28.2 AFP ALB MIR21 MIR301A
34 hepatitis b vaccine, response to 12.2
35 hepatitis b reinfection following liver transplantation 12.0
36 hepatocellular carcinoma 11.6
37 gianotti crosti syndrome 11.3
38 membranous nephropathy 11.2
39 polyarteritis nodosa 11.2
40 acrodermatitis 11.2
41 hepatoblastoma 11.2
42 childhood hepatocellular carcinoma 11.2
43 lymphomatoid granulomatosis 11.1 IFNA1 IFNA2
44 squamous papillomatosis 11.1 IFNA1 IFNA2
45 adult dermatomyositis 11.0 GPT MBL2 TNF
46 human immunodeficiency virus infectious disease 11.0 APOBEC3G IFNA1 TNF
47 null-cell leukemia 11.0 IFNA1 TNF
48 viral infectious disease 10.9 GPT IFNA1 IFNA2 TNF
49 vulvar vestibulitis syndrome 10.9 MBL2 TNF
50 protein-energy malnutrition 10.9 ALB GPT TNF

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B
Sources

Symptoms & Phenotypes for Hepatitis B

About this section

Symptoms:

12
  • • fever
  • • fatigue
  • • loss of appetite
  • • nausea
  • • vomiting
  • • abdominal pain
  • • clay-colored bowel movements
  • • joint pain
  • • jaundice

UMLS symptoms related to Hepatitis B:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas
Sources

Drugs & Therapeutics for Hepatitis B

About this section

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 488)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
2
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
3
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
4
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
7
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
8
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
9
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
12
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
13
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
14
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 8008-53-5
15
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
16
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
18
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
19
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
20
Simethicone Approved Phase 4,Phase 3 8050-81-5
21
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
22
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
23
Zidovudine Approved Phase 4,Phase 2,Not Applicable 30516-87-1 35370
24
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
25
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
26
Lenograstim Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 135968-09-1
27
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
28
Ethanol Approved Phase 4,Phase 1,Not Applicable 64-17-5 702
29
Ledipasvir Approved Phase 4,Phase 2,Phase 3 1256388-51-8 67505836
30
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
31
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 1 54-05-7 2719
32
Adalimumab Approved Phase 4 331731-18-1 16219006
33
Etanercept Approved, Investigational Phase 4 185243-69-0
34
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
35
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
36
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
37
Cobicistat Approved Phase 4,Phase 3,Phase 2 1004316-88-4
38
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
41 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
42
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
43
Levonorgestrel Approved, Investigational Phase 4,Not Applicable 797-63-7, 17489-40-6 13109
44
Polyestradiol phosphate Approved Phase 4 28014-46-2
45
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
46
Infliximab Approved Phase 4 170277-31-3
47
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
48
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
49
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
50
Methadone Approved Phase 4,Phase 3,Not Applicable 76-99-3 4095

Interventional clinical trials:

(show top 50) (show all 1608)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
5 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
6 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
7 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
8 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
9 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
10 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
11 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
12 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
13 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
14 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
15 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
16 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
17 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
18 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
19 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
20 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
21 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
22 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
23 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
24 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
25 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
26 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
27 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
28 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
29 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
30 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
31 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
32 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
33 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
34 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
35 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
36 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
37 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
38 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
39 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
40 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
41 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine
42 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
43 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
44 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
45 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
46 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
47 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
48 EFFORT Extension Study Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
49 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
50 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Sources

Genetic Tests for Hepatitis B

About this section
Sources

Anatomical Context for Hepatitis B

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

19
Liver

MalaCards organs/tissues related to Hepatitis B:

41
Liver, T Cells, Testes, Kidney, Bone, Skin, B Cells
Sources

Publications for Hepatitis B

About this section

Articles related to Hepatitis B:

(show top 50) (show all 5683)
# Title Authors Year
1
Solid-state [<sup>13</sup>C-<sup>15</sup>N] NMR resonance assignment of hepatitis B virus core protein. ( 29450824 )
2018
2
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
3
Immunoreaction-Mediated Aggregation of Gold Nanoparticles for Sensitive and Selective Assay of Hepatitis B Surface Antigen. ( 29448537 )
2018
4
Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. ( 29975729 )
2018
5
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. ( 29781346 )
2018
6
A Case of Acute Autoimmune Hepatitis Superimposed on Chronic Hepatitis B Infection. ( 29805819 )
2018
7
A cross-sectional study of the relationship between infant Thimerosal-containing hepatitis B vaccine exposure and attention-deficit/hyperactivity disorder. ( 29413097 )
2018
8
Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report. ( 29923995 )
2018
9
PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION. ( 29446468 )
2018
10
Hepatitis B virus infection and the risk of cancer in the elderly US population. ( 29974477 )
2018
11
Fluorescent protein tagged hepatitis B virus capsid protein with long glycine-serine linker that supports nucleocapsid formation. ( 29447911 )
2018
12
Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable? ( 29353268 )
2018
13
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. ( 29775812 )
2018
14
Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. ( 29447614 )
2018
15
Facile synthesis of MoS<sub>2</sub>@Cu<sub>2</sub>O-Pt nanohybrid as enzyme-mimetic label for the detection of the Hepatitis B surface antigen. ( 28982091 )
2018
16
Effect of tenofovir on renal function in patients with chronic hepatitis B. ( 29443737 )
2018
17
Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. ( 29437960 )
2018
18
Hepatitis B vaccination coverage among health-care workers in Africa: A systematic review and meta-analysis. ( 29970299 )
2018
19
Molecular evolution and phylodynamics of hepatitis B virus infection circulating in Iran. ( 29442226 )
2018
20
Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. ( 29979437 )
2018
21
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
22
What Are the Main Differences in the Treatment of Chronic Hepatitis B between Korean Children and Adults? ( 29441758 )
2018
23
Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. ( 29388206 )
2018
24
Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration. ( 29414802 )
2018
25
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
26
Amyotrophic neuralgia of atypical presentation associated with exposure to a hepatitis B vaccine. ( 29789233 )
2018
27
Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. ( 29698488 )
2018
28
Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )
2018
29
Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study. ( 29452204 )
2018
30
TIP60 Complex Inhibits Hepatitis B Virus Transcription. ( 29321313 )
2018
31
Opisthorchiasis and viral hepatitis b: clinical cases. ( 29602941 )
2018
32
Lack of Association between Oral Lichen Planus and Hepatitis B and C Virus Infection - a Report from Southeast Iran ( 29936791 )
2018
33
Safety Proi-8le of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. ( 29972221 )
2018
34
On hepatitis B virus and vasculitis. ( 29948001 )
2018
35
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. ( 29844854 )
2018
36
Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection? ( 29970751 )
2018
37
Hepatitis B virus genotypes A1, A2 and E in Cape Verde: Unequal distribution through the islands and association with human flows. ( 29447232 )
2018
38
Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. ( 29963464 )
2018
39
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
40
The Role of Renal Angiography in Hepatitis B-related Polyarteritis Nodosa. ( 29515309 )
2018
41
3D microfluidic liver cultures asA a physiological preclinical tool for hepatitis B virus infection. ( 29445209 )
2018
42
Prevalence estimates of HIV, syphilis, hepatitis B and C among female sex workers (FSW) in Brazil, 2016. ( 29912817 )
2018
43
Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation. ( 29450703 )
2018
44
MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. ( 29416678 )
2018
45
Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. ( 29974410 )
2018
46
Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job? ( 29942730 )
2018
47
Association between HLA class II alleles and hepatitis B virus infection in Transylvania, Romania. ( 29979894 )
2018
48
Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. ( 29451182 )
2018
49
An Uncommon Case of Bilateral Pathologic Hip Fractures: Antiviral Drug-induced Osteomalacia in a Patient with Hepatitis B. ( 29896460 )
2018
50
Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. ( 29970037 )
2018
Sources

Variations for Hepatitis B

About this section
Sources

Expression for Hepatitis B

About this section
Search GEO for disease gene expression data for Hepatitis B.
Sources

Pathways for Hepatitis B

About this section

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.23 IFNA1 IFNA2 IFNAR2 TNF
2
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.17 IFNA1 IFNA2 IFNAR2 LAMTOR5 TNF
3
Tuberculosis 37
11.99 IFNA1 IFNA2 IL10RB TNF
4
Regulation of IFNA signaling 66
Show member pathways
 11.95 IFNA1 IFNA2 IFNAR2 IL10RB TNF
5
Necroptosis 37
Show member pathways
 11.94 IFNA1 IFNA2 IFNAR2 TNF
6
Jak-Stat Signaling Pathway 67
11.57 IFNA1 IFNA2 IFNAR2 IL10RB
7
Hepatitis C 37
11.57 IFNA1 IFNA2 IFNAR2 TNF
8
FOXA2 and FOXA3 transcription factor networks 1
11.19 AFP ALB F2
9
Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics 61
Show member pathways
 10.16 IFNA2 IFNAR2 IL10RB
Sources

GO Terms for Hepatitis B

About this section

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 AFP ALB CPD F2 GPT IFNA1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 IFNA2 MIR17 MIR21 TNF
2 response to virus GO:0009615 9.7 IFNAR2 LAMTOR5 TNF
3 cytokine-mediated signaling pathway GO:0019221 9.65 IFNA1 IFNA2 IFNAR2 IL10RB TNF
4 type I interferon signaling pathway GO:0060337 9.63 IFNA1 IFNA2 IFNAR2
5 humoral immune response GO:0006959 9.61 IFNA1 IFNA2 TNF
6 natural killer cell activation involved in immune response GO:0002323 9.54 IFNA1 IFNA2
7 negative regulation of growth of symbiont in host GO:0044130 9.51 MBL2 TNF
8 positive regulation of metalloendopeptidase activity GO:1904685 9.48 MIR17 MIR21
9 negative regulation of viral process GO:0048525 9.4 APOBEC3G MBL2
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR17 MIR21
11 defense response to virus GO:0051607 9.35 APOBEC3G IFNA1 IFNA2 IFNAR2 IL10RB
12 regulation of type I interferon-mediated signaling pathway GO:0060338 9.33 IFNA1 IFNA2 IFNAR2
13 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.32 MIR21 TNF
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 MIR17 MIR21 MIR301A TNF

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2
Sources

Sources for Hepatitis B

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
61